Notices. Notice

5,702 words·~26 min read·/register/2007/05/30/07-2660

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4140-01-M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Use of Cripto-1 as Claimed in the Licensed Patent Rights, for the Development of a FDA Approved Diagnostic Kit for Human Cancers AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S.

Patent No. 7,078,176; European Patent No. 1370869 and PCT Application No. PCT/US02/02225 and foreign equivalents thereof entitled “Detection and quantification of Cripto-1” (E-290-2000/0), to Biosite, Inc, which is located in San Diego, California. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of the Licensed Patent Rights, for the development of a FDA approved diagnostic kit for human cancers.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 30, 2007 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Michelle A. Booden, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;

Telephone:

(301)451-7337; Facsimile:

(301)402-0220; E-mail: *boodenm@mail.nih.gov.* SUPPLEMENTARY INFORMATION: Cripto-1

(CR1)is a member of the epidermal growth factor (EGF)-related families of peptides and is involved in the development and progression of various human carcinomas. In particular, CR1 overexpression has been detected in 50-90% of carcinomas of the colon, pancreas, stomach, gallbladder, breast, lung, endometrium and cervix. Current methodologies of cancer detection, *e.g.* immunohistochemistry, can be time consuming, inconvenient and oftentimes, inaccurate, and therefore, a need exists for more efficient, reliable and less time consuming methods of detection. The invention relates to such a method of detection. The inventors disclose methods for the detection and quantification of CR1 in human milk, using an ELISA-based protocol. This test could also be used to more effectively detect and perhaps stage cancers. Additionally, should particular tumor cells, *e.g.* breast tumor cells, express a sufficiently high level of CR1, it may be possible to use the assay to detect and measure CR1 in human serum and/or plasma. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty

(60)days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: May 22, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7-10352 Filed 5-29-07; 8:45 am] BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of Anti-HIV Therapeutics, Anti-HIV Topical Microbicides, and Anti-Breast Cancer Therapeutics AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in: PCT/US99/13856 filed June 18, 1999, preceded by U.S. Provisional Patent Application Serial No. 60/089,842 (HHS Ref. E-136-1998/0-US-01), filed June 19, 1999, entered the national stage filing in June 1999 in Korea Patent Application No. 10-2000-7014479; in Mexico Patent Application No. 012525; in Australia Patent Application No. 46972/99; in Canada Patent Application No. 2335464; in Brazil Patent Application No. PI9911385-6; in U.S. Patent No. 6,706,729 and filed DIV in U.S. Patent Application No. 10/738,062 in December 2003; in EPO Patent Application No. 99930428.0 and validated in Germany, France, United Kingdom, Italy and Ireland in November 2006, entitled “Novel Thioesters and Uses Thereof”, Inventors: Drs. James A. Turpin (NCI), Yongsheng Song (NCI), John K. Inman (NIAID), Mingjun Huang (NCI), Anders Wallqvist (NCI), Andrew Maynard (NCI), David G. Covell (NCI), William G. Rice (NCI), and Ettore Appella (NCI); PCT/US02/23924 filed July 25, 2002, preceded by U.S. Provisional Patent Application Serial No. 60/310,133 (E-329-2000/0-US-01), filed August 3, 2001, entered the national stage filing in February 2004 in EPO Patent Application No. 02756732.0; in Australia Patent Application No. 2003322721; in Canada Patent Application No. 2456083 and U.S. Patent Application No. 10/485,165, entitled “Acylthiols and Component Thiol Compositions as Anti-HIV and Anti-Retroviral Agents”, Inventors: Drs. John K. Inman (NIAID), Atul Goel (NCI), Ettore Appella (NCI), and Jim A. Turpin (NCI); to ImQuest Pharmaceuticals Inc. (Hereafter ImQuest), having a place of business in Frederick, Maryland. The patent rights in these inventions have been assigned to the United States of America. DATES: Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 30, 2007 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Sally Hu, Ph.D., M.B.A., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; E-mail: *hus@od.nih.gov;* Telephone:

(301)435-5606; Facsimile:

(301)402-0220. SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. E-136-1998/0-US-01 describes composition claims for a novel family of thiolesters and uses thereof. These thiolesters are capable of inactivating viruses by a variety of mechanisms, particularly by complexing with metal ion-complexing zinc fingers. The invention further provides for methods for inactivating a virus, particularly human immunodeficiency virus (HIV), using these compounds, and thereby also inhibiting transmission of the virus. E-329-2000/0-US-01 provides a novel family of acylthiols, and polypeptides, pharmaceutical compositions, devices and other materials containing them, and uses thereof. More specifically, this invention provides covalent (irreversible) inhibitors of HIV that selectively target its highly conserved nucleocapsid protein

(NCp7)by dissociating a metal ion from a zinc finger-containing protein. Because of the mutationally intolerant nature of NCp7, drug resistance is much less likely to occur with drugs attacking this target. In addition, these drugs should inactivate all types and strains of HIV and could also inactivate other retroviruses since most retroviruses share one or two highly conserved zinc fingers that have the Cys-Cys-His-Cys motif of the NCp7. Finally, this invention could be very useful for the large-scale practical synthesis of HIV inhibitors because these compounds can be prepared from inexpensive starting materials and facile reactions. Thus, it opens the possibility that an effective drug treatment for HIV could reach underdeveloped countries. The field of use may be limited to the development of anti-HIV therapeutics, anti-HIV topical microbicides and anti-breast cancer therapeutics. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Date: May 22, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7-10334 Filed 5-29-07; 8:45 am] BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Proteomics in Cancer Diagnostics and Therapy AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), a federal agency under the Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the invention embodied in HHS Ref. No. E-261-1998 “Methods and Devices for Isolation and Analysis of Cellular Protein Content;” U.S. Patent 6,969,614; and E-039-2003/0 “Combinatorial Therapy for Protein Signaling Diseases,” U.S. Patent Application No. 10/798,799 filed March 10, 2004; to Theranostics Health, LLC, a Limited Liability Company formed under the laws of the state of Delaware and having a principle place of business in Rockville, Maryland. The United States of America is the assignee of the patent rights in the above inventions. The contemplated exclusive license may be granted a field limited to proteomic diagnostics for cancer requiring regulatory approval. DATES: Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before July 30, 2007 will be considered. ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Michael A. Shmilovich, Esq., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:

(301)435-5019; Facsimile:

(301)402-0220; E-mail: *shmilovm@mail.nih.gov.* A signed confidentiality nondisclosure agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: The patent applications intended for licensure disclose and/or cover the following: E-039-2003 “Combinatorial Therapy for Protein Signaling Diseases” The invention is drawn to methods for individualizing therapy based on information obtained concerning deranged signaling pathways that cause disease. The invention includes the use of protein microarrays to detect the deranged signaling pathways that are specific for the subject's disease. The invention covers the use of combination therapy targeting multiple points in the protein network. The invention is based, in part, on the unexpected discovery that treatment of interconnected nodes in a protein signaling pathway can provide a synergistic improvement in therapeutic efficacy at reduced toxicity. For example, a protein signaling network of a diseased cell (e.g., colon cancer) is analyzed and the information obtained from the analysis is used to select at least two drugs whose targets are interconnected within the protein signaling network. E-261-1998 “Methods and Devices for the Isolation and Analysis of Cellular Protein Content” The invention is a comprehensive Laser Capture Microdissection

(LCM)method for determining protein characteristics of a sample tissue cell to quantitatively discern and compare the protein content of healthy cells versus diseased cells. The tissue source of a tumor metastasis is available from the acquisition of this information. The focus in molecular biology is moving from genomics to proteomics, the study of variations in the protein levels of cells, caused by the state of the cell itself, whether healthy or unhealthy. The invention provides a method for using new and innovative methods for cell analysis. Previous methods, such as UV-laser ablation of unwanted tissue regions and oil well isolation of tissue cells, were complex, labor intensive, and did not utilize protein stabilizers. Direct comparisons between healthy cells and tumor cells were not made due to limitations of the methods. The new method consists of first using the new LCM method to obtain pure cell populations. Next, the sample is placed in a device so that the proteins are solubilized. Then the immunological and biochemical methods and subsequent analyses are performed. These techniques include (but are not limited to) immunoassays, 1D and 2D gel electrophoresis characterization, Western blotting, Matrix Assisted Laser Desorption Ionization/Time of Flight (MALDI/TOF) and Surface Enhanced Laser Desorption Ionization Spectroscopy (SELDI), Protein Arrays and Phosphoprotein Fingerprinting. The methods listed above allow for the direct comparison of both qualitative and quantitative tissue content of healthy and diseased cells, from the same sample. The sequential method of using LCM, protein isolation, analysis and comparison is superior to existing methods because the location of the tumor can be found simply using immunohistochemistry, and protein characteristics, such as amino acid sequence and binding ability can also be discerned. In addition, by using protein fingerprinting, the source of the tumor metastasis is found effectively. The invention has been tested extensively with the different methods listed above. This technology can be used in hospitals and research pathology labs for quantitative measure of protein characteristics of cells. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within sixty

(60)days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: May 21, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7-10354 Filed 5-29-07; 8:45 am] BILLING CODE 4140-01-P DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS-2007-0031] Science and Technology Directorate; Submission for Review; New Information Collection Request for Support of TechSolutions New Account Request Data Form, New Capability Gap Data Form, and Feedback Data Form AGENCY: Science and Technology Directorate, DHS. ACTION: 60 day notice and request for comment. SUMMARY: The Department of Homeland Security

(DHS)TechSolutions program is responsible for providing information, technology, and training to the first responder community. The TechSolutions program will use web-based technology to collect submitter and capability gap information. DHS is soliciting public comment on the New Account Request Data (DHS Form 10015), New Capability Gap Data (DHS Form 10011), and Feedback Data (DHS Form 10012) forms and instructions (hereinafter “Forms Package”) designed to collect submitter and capability gap information from first responders (federal, state, local, and tribal police, firefighters, and Emergency Medical Service) through the TechSolutions Web site. This notice and request for comments is required by the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. chapter 35). DATES: Comments are encouraged and will be accepted until July 30, 2007. ADDRESSES: You may submit comments, identified by docket number DHS-2007-0031, by one of the following methods: • *Federal eRulemaking Portal: http://www.regulations.gov.* Follow the instructions for submitting comments. • *E-mail: ken.rogers@dhs.gov.* Include docket number DHS-2007-0031 in the subject line of the message. • *Mail:* Science and Technology Directorate, ATTN: OCIO/Ken Rogers, 245 Murray Drive, Bldg 410, Washington, DC 20528. FOR FURTHER INFORMATION CONTACT: Ken Rogers

(202)254-6185 (this is not a toll free number). SUPPLEMENTARY INFORMATION: DHS invites the general public to comment on the new information collection forms, as described below. Interested parties can obtain copies of the Forms Package by calling or writing the point of contact listed above. Please note that the Forms Package include three forms for collecting submitter and capability gap information from first responders (federal, state, local, and tribal police, firefighters, and Emergency Medical Service). As explained herein, these separate forms are intended to be flexible and permit DHS S&T to address reported capability gaps, leading to improved safety and productivity without undue bureaucratic burden. The Department is committed to improving its TechSolutions processes and urges all interested parties to suggest how these materials can further reduce burden while seeking necessary information under the Act. DHS is particularly interested in comments that:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3)Suggest ways to enhance the quality, utility, and clarity of the information to be collected; and

(4)Suggest ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.* , permitting electronic submissions of responses. Overview of this Information Collection:

(1)*Type of Information Collection:* New information collection.

(2)*Title of the Form/Collection:* TechSolutions New Account Request Data Form, New Capability Gap Data Form, and Feedback Data Form.

(3)*Agency Form Number, if any, and the applicable component of the Department of Homeland Security sponsoring the collection:* New Account Request Data—DHS Form 10015, New Capability Gap Data—DHS Form 10011, and Feedback Data—DHS Form 10012

(4)*Affected public who will be asked or required to respond, as well as a brief abstract:* Business or other for-profit, not-for profit institutions, and state, local or tribal government; the data collected through the TechSolutions Forms Package will be used to address reported capability gaps, leading to improved safety and productivity for first responders.

(5)An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: New Account Request Data Form (DHS Form 10015)—75,000 respondents annually/30 minutes per respondent, New Capability Gap Data Form (DHS Form 10011)—500 respondents annually/2 hours per respondent, and Feedback Data Form (DHS Form 10012)—500 respondents annually/30 minutes per respondent.

(6)An estimate of the total public burden (in hours) associated with the collection: 38,750 burden hours. Dated: April 19, 2007. Kenneth D. Rogers, Chief Information Officer. [FR Doc. E7-10382 Filed 5-29-07; 8:45 am] BILLING CODE 4410-10-P DEPARTMENT OF HOMELAND SECURITY Bureau of Immigration and Customs Enforcement Agency Information Collection Activities: Extension of an Existing Information Collection; Comment Request ACTION: 30-day notice of information collection under review; Form G-146, Nonimmigrant checkout letter; OMB Control No. 1653-0020. The Department of Homeland Security, U.S. Immigration and Customs Enforcement (USICE), has submitted the following information collection request for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the **Federal Register** on March 30, 2007, Vol. 72, No. 61, 15143-4, allowing for a 60-day public comment period. No comments were received on this information collection. The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted for thirty days until June 29, 2007. Written comments and suggestions regarding items contained in this notice, and especially with regard to the estimated public burden and associated response time should be directed to the Department of Homeland Security (DHS), Ricardo Lemus, Chief, Records Management Branch, Bureau of Immigration and Customs Enforcement, 425 I Street, NW., Room 1122, Washington, DC 20536;

(202)514-3211. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.* , permitting electronic submission of responses. Overview of this information collection:

(1)*Type of Information Collection:* Extension of currently approved information collection.

(2)*Title of the Form/Collection:* Order to Show Cause.

(3)*Agency form number, if any, and the applicable component of the Department of Homeland Security sponsoring the collection:* Form G-146, Bureau of Immigration and Customs Enforcement.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* Individual or Households. When an alien (other than one who is required to depart under safeguards) is granted the privilege of voluntary departure without the issuance of an Order to Show Cause, a control card is prepared. If, after a certain period of time, a verification of departure is not received, actions are taken to locate the alien or ascertain his or her whereabouts. Form G-146 is used to inquire of persons in the United States or abroad regarding the whereabouts of the alien.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* 20,000 responses at 10 minutes (.16) per response.

(6)*An estimate of the total public burden (in hours) associated with the collection:* 3,220 annual burden hours. Comments and/or questions; requests for a copy of the proposed information collection instrument, with instructions; or inquiries for additional information should be directed to: Ricardo Lemus, Chief, Records Management Branch, Bureau of Immigration and Customs Enforcement, 425 I Street, NW., Room 1122, Washington, DC 20536;

(202)616-2266. Dated: May 16, 2007. Ricardo Lemus, Chief, Records Management Branch, Bureau of Immigration and Customs Enforcement, Department of Homeland Security. [FR Doc. E7-10296 Filed 5-29-07; 8:45 am] BILLING CODE 9110-A3-P DEPARTMENT OF HOMELAND SECURITY Bureau of Immigration and Customs Enforcement Agency Information Collection Activities: Extension of an Existing Information Collection; Comment Request ACTION: 30-Day Notice of Information Collection Under Review; Form I-901, Fee Remittance for Certain F, J and M Nonimmigrants; OMB Control No. 1653-0034 The Department of Homeland Security, U.S. Immigration and Customs Enforcement (USICE), has submitted the following information collection request for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the **Federal Register** on March 30, 2007, Vol. 72 No. 61 15144, allowing for a 60-day comment period. No comments were received on this information collection. The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted for thirty days until June 29, 2007. Written comments and suggestions regarding items contained in this notice, and especially with regard to the estimated public burden and associated response time should be directed to the Department of Homeland Security (DHS), Ricardo Lemus, Chief, Records Management Branch, Bureau of Immigration and Customs Enforcement, 425 I Street, NW., Room 1122, Washington, DC 20536;

(202)514-3211. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(1)*Type of Information Collection:* Extension of currently approved information collection.

(2)*Title of the Form/Collection:* Fee Remittance for Certain F, J and M Nonimmigrants.

(3)*Agency form number, if any, and the applicable component of the Department of Homeland Security sponsoring the collection:* Form I-901, Bureau of Immigration and Customs Enforcement.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* Individual or Households. Public Law 104-208, Subtitle D, Section 641 directs the Attorney General, in consultation with the Secretary of State and the Secretary of Education, to develop and conduct a program to collect information on nonimmigrant foreign students and exchange visitors from approved institutions of higher education, as defined in section 101(a) of the Higher Education Act of 1965, as amended or in a program of study at any other DHS-approved academic or language-training institution, to include approved private elementary and secondary schools and public secondary schools, and from approved exchange visitor program sponsors designated by the Department of State (DOS). It also authorized a fee, not to exceed $100, to be collected from these students and exchange visitors to support this information collection program. DHS has implemented the Student and Exchange Visitor Information System (SEVIS) to carry out this statutory requirement.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* 600,000 responses at 19 minutes (.32) per response.

(6)*An estimate of the total public burden (in hours) associated with the collection:* 192,000 annual burden hours. Comments and/or questions; requests for a copy of the proposed information collection instrument, with instructions; or inquiries for additional information should be directed to: Ricardo Lemus, Chief, Records Management Branch, Bureau of Immigration and Customs Enforcement, 425 I Street, NW., Room 1122, Washington, DC 20536;

(202)616-2266. Dated: May 16, 2007. Ricardo Lemus, Chief, Records Management Branch, Bureau of Immigration and Customs Enforcement, Department of Homeland Security. [FR Doc. E7-10297 5-29-07; 8:45 am] BILLING CODE 4410-10-P DEPARTMENT OF THE INTERIOR Bureau of Land Management [AA-6695; AK-964-1410-KC-P] Alaska Native Claims Selection AGENCY: Bureau of Land Management, Interior. ACTION: Notice of decision approving lands for conveyance. SUMMARY: As required by 43 CFR 2650.7(d), notice is hereby given that an appealable decision approving lands for conveyance pursuant to the Alaska Native Claims Settlement Act will be issued to The Port Graham Corporation. The lands are in the vicinity of Port Graham, Alaska, and are located in: Tract A, U.S. Survey 1642, Alaska. Containing 1.01 acres. The subsurface estate in these lands will be conveyed to Chugach Alaska Corporation when the surface estate is conveyed to The Port Graham Corporation. Notice of the decision will also be published four times in the Homer Tribune. DATES: The time limits for filing an appeal are: 1. Any party claiming a property interest which is adversely affected by the decision shall have until June 29, 2007 to file an appeal. 2. Parties receiving service of the decision by certified mail shall have 30 days from the date of receipt to file an appeal. Parties who do not file an appeal in accordance with the requirements of 43 CFR Part 4, Subpart E, shall be deemed to have waived their rights. ADDRESSES: A copy of the decision may be obtained from: Bureau of Land Management, Alaska State Office, 222 West Seventh Avenue, #13, Anchorage, Alaska 99513-7504. FOR FURTHER INFORMATION, CONTACT: The Bureau of Land Management by phone at 907-271-5960, or by e-mail at *ak.blm.conveyance@ak.blm.gov.* Persons who use a telecommunication device

(TTD)may call the Federal Information Relay Service

(FIRS)at 1-800-877-8330, 24 hours a day, seven days a week, to contact the Bureau of Land Management. Jennifer L. Noe, Land Law Examiner, Branch of Adjudication II. [FR Doc. E7-10314 Filed 5-29-07; 8:45 am] BILLING CODE 4310-$$-P INTERNATIONAL TRADE COMMISSION [Investigation No. 337-TA-584] In the Matter of Certain Alendronate Salts and Products Containing Same; Notice of Commission Decision Not To Review an Initial Determination Granting a Motion To Withdraw the Complaint and Terminate the Investigation AGENCY: U.S. International Trade Commission. ACTION: Notice. SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (“ID”) (Order No. 12) issued by the presiding administrative law judge (“ALJ”) granting complainant's motion to withdraw the complaint and terminate the above-referenced investigation. FOR FURTHER INFORMATION CONTACT: Christal A. Sheppard, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone

(202)708-2301. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone

(202)205-2000. General information concerning the Commission may also be obtained by accessing its Internet server at *http://www.usitc.gov.* The public record for this investigation may be viewed on the Commission's electronic docket

(EDIS)at *http://edis.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on

(202)205-1810. SUPPLEMENTARY INFORMATION: This investigation was instituted on September 22, 2006, based on a complaint filed by Merck & Co., Inc., of Whitehouse Station, New Jersey. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain alendronate salts and products containing the same by reason of infringement of claims 1-5 of United States Patent No. 4,922,007. The complaint further alleges that an industry exists as required by subsection (a)(2) of section 337. The complaint named CIPLA, Ltd., of Mumbai, India as respondent in this investigation. On February 26, 2007, the complainant filed a motion to terminate the investigation as to all parties based on withdrawal of the complaint, pursuant to 19 CFR 210.21(a). On April 30, 2007, the ALJ issued an ID (Order No. 12) granting the complainant's motion. No petitions for review were received and the Commission has determined not to review this ID. Accordingly, the above-captioned investigation is hereby terminated. The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in sections 210.42(h) of the Commission's Rules of Practice and Procedure (19 CFR 210.42(h)). By order of the Commission. Issued: May 23, 2007. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E7-10320 Filed 5-29-07; 8:45 am] BILLING CODE 7020-02-P INTERNATIONAL TRADE COMMISSION [Investigation No. 337-TA-591] In the Matter of Certain Wireless Conference Calling Devices, Components Thereof, and Devices Containing the Same; Notice of Commission Decision Not To Review Initial Determination Granting Motion To Withdraw Complaint and Terminate Investigation AGENCY: U.S. International Trade Commission. ACTION: Notice. SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review the presiding administrative law judge's (“ALJ”) initial determination (“ID”) (Order No. 3) granting the motion to withdraw the complaint and terminate the above-captioned investigation. FOR FURTHER INFORMATION CONTACT: Eric Frahm, Office of the General Counsel, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone

(202)205-3107. Copies of the ALJ's ID and all other non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone

(EDIS)at *http://edis.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on

(202)205-1810. SUPPLEMENTARY INFORMATION: On January 31, 2007, the Commission instituted an investigation under section 337 of the Tariff Act of 1930, 19 U.S.C. 1337, based on a complaint (December 29, 2006) and supplemental complaint (January 17, 2007) filed by Callpod, Inc. of Chicago, Illinois, alleging a violation of section 337 in the importation, sale for importation, and sale within the United States after importation of certain wireless conference calling devices, components thereof, and devices containing same by reason of infringement of claims 1, 3, 6, 9, 10, 12, and 15 of U.S. Patent No. 6,801,611. 72 FR 5300-01 (February 5, 2007). The complaint, as supplemented, named GN Netcom, Inc. of Nashua, NH; GN Netcom A/S of Ballerup, Denmark; and GN Store Nord A/S of Ballerup, Denmark as respondents. On April 5, 2007, the complainant moved to withdraw the complaint and terminate the investigation. On April 16, 2007, the Commission Investigative Staff filed a response in support of complainant's motion to withdraw the complaint. On April 18, 2007, respondents filed a response in partial opposition to complainant's motion to withdraw. On April 30, 2007, the ALJ issued an ID (Order No. 3) (copy attached) granting the motion to withdraw the complaint and terminate the investigation. The ALJ found no indication that termination of the investigation would adversely affect the public interest, and that the procedural requirements for terminating the investigation had been met. No petitions for review were filed. The Commission has determined not to review the ID. The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in section 210.42 of the Commission's Rules of Practice and Procedure (19 CFR 210.42). By order of the Commission. Issued: May 24, 2007. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E7-10293 Filed 5-29-07; 8:45 am] BILLING CODE 7020-02-P DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting *Time and Date:* 9 a.m. to 4:30 p.m. on Monday, June 1, 2007, 9 a.m. to 4:30 p.m. on Tuesday, June 12, 2007. *Place:* National Correctional, Training Academy & Information Center, 791 Chambers Road, Aurora, Colorado 80011, Tel: 303-365-4450. *Status:* Open. *Matters To Be Considered:* Tour of the new Academy & Information Center in Aurora, Colorado; Live Demonstration of Distance Learning; meeting the New Deputy Director Thomas Beauclair; Norval Morris Project; Agency Reports; Quarterly Report by Office of Justice Programs; U.S. Parole Commission; American Corrections Association; Federal Judicial Center. *Contact Person for More Information:* Thomas Beauclair, Deputy Director, 202-307-3106, ext. 44254. Morris L. Thigpen, Director. [FR Doc. 07-2660 Filed 5-29-07; 8:45 am]

Connectionstraces to 6

Traces to 6 documents

U.S. Code

CFR

4 references not yet in our index